At a glance

ClinicalIndex Comparison Record

Phase 2Completed· 24 enrolled

Drug / intervention

Banaba +1 moredrug

Likely dose

Banaba 500 mgfrom record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02767869

NCT02767869Phase 2Completed

Compare CT.gov

Effect of Banaba (Lagerstroemia Speciosa) on Metabolic Syndrome, Insulin Secretion and Insulin Sensitivity

University of Guadalajara·interventional·Posted May 10, 2016·Updated Jan 14, 2021

In Brief

A Phase 2 clinical trial evaluating Banaba and placebo for Metabolic Syndrome X. Completed, enrolled 24 participants across 1 site.

Detailed Summary

The Metabolic Syndrome is a high prevalence disease worldwide. About a quarter of the adult population suffers the disease. Banaba has shown evidence that has on metabolic syndrome, insulin sensitivity and insulin secretion. The investigators hypothesis was that the the administration of resveratrol modifies the metabolic syndrome, insulin sensitivity and insulin secretion.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsMetabolic Syndrome X

CountriesMexico

Collaborators--

Timeline

Phase 2CompletedFinished

201520162017201820192020202120222023202420252026

Enrollment StartJan 2015

First PostedMay 2016

Primary CompletionDec 2016

Study CompletionFeb 2017

TodayJul 2026

First PostedMay 10, 2016

Enrollment StartJan 1, 2015

Primary CompletionDec 1, 2016

Study CompletionFeb 1, 2017

TodayJul 2, 2026

Enrollment to primary: 1.9 yearsPosted 10.1 years ago

Interventions

Banabadrug

Banaba capsules of 500 mg two times per day before meals with a total dosis of 1000 mg per day.

placebodrug

Calcined magnesia capsule, 500 mg, two times per day before meals with a total dose per day of 1000 mg